Paloma Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Paloma Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-800	Closed	-$194K	–	1130
2024 Q2	$194K	Buy	+800	New	+$126K	0.01%	1004
2023 Q4	–	Sell	-1,700	Closed	-$301K	–	729
2023 Q3	$301K	Buy	+1,700	New	+$324K	0.01%	546
2020 Q4	–	Sell	-5,200	Closed	-$757K	–	1605
2020 Q3	$757K	Buy	+5,200	New	+$739K	0.02%	905
2018 Q3	–	Sell	-11,800	Closed	-$1.16M	–	1510
2018 Q2	$1.16M	Buy	+11,800	New	+$1.17M	0.02%	661

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paloma Partners's ALNY Position: Q3 2024 in Review

Paloma Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 378 shares — an estimated $91.9K sold.

Paloma Partners first reported a position in ALNY in Q3 2013 and held it in 23 quarters. The position peaked at $7.89M in Q2 2014. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

Paloma Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 378 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $91.9K.
Paloma Partners first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 23 quarters.
Paloma Partners's Alnylam Pharmaceuticals position peaked at $7.89M in Q2 2014.
567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.